in 149 countries, including 5,000 in France.
98% of Servier drugs
active principles are synthesized in its own plant in Bolbec-Baclair in France.
100 Million patients
treated daily with Servier medicinal products and generics.
5 major R&D areas
cardiovascular, immune-inflammatory and neuropsychiatric diseases, cancer and diabetes.
33 drug candidates
in research and development, including 23 new molecular entities.
15 international centers of clinical development
and 3 research centers.
16 chemical and pharmaceutical production sites
producing chemicals and pharmaceuticals worldwide.
€4,2 billion euros in revenue
comprising €2.9 billion for branded drugs and €1.3 billion for generics.
25 % of turnover from Servier drugs is invested in R&D
No. 1 independant french pharmaceutical company
no. 33 in the world; 3 research centres including 2 in France.
No.1 in cardiology in France
no. 2 in Europe, No. 5 in the world.
2nd leading preferred partner for research centers conducting clinical trials
According to CenterWatch rankings from March 2017, based on a total of 23 pharmaceutical companies
Servier earned the highest score of A3++
As in previous years, this high score represents excellence in honoring financial commitments.
Participation reached 36,6% of the trade balance surplus in France
In pharmaceuticals and fine chemicals, amouting to €1.4 billion.